Phuturdex › Diseases › Thyroid neoplasm
Drugs in development · updated 30 October 2026
Thyroid neoplasm: drugs in development
As of 30 October 2026 there are 67 active clinical trials (recruiting or ongoing, phases I–III) on 99 drugs for thyroid neoplasm. 37 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CabozantinibResniben®, Cabometyx® | III | 1 | NCT03690388 |
| DexmedetomidineIgalmi®, Precedex® | II–III | 1 | NCT07434206 |
| MetforminRiomet Er®, Glumetza® | III | 1 | NCT05468554 |
| TrametinibMekinist®, Spexotras® | I–II | 7 | NCT05275374 |
| PembrolizumabKEYTRUDA, MK-3475 | I–II | 6 | NCT05620134 |
| SelpercatinibLOXO-292, Retevmo® | I–II | 6 | NCT03157128 |
| DabrafenibTafinlar®, Finlee® | II | 5 | NCT02465060 |
| NivolumabOpdivo, ONO-4538 | II | 5 | NCT02465060 |
| LenvatinibLenvatinib Mesilate Capsules, Levatinib | I–II | 4 | NCT05620134 |
| BinimetinibMEK162, Mektovi® | II | 3 | NCT02465060 |
| CyclophosphamideCyclophosphamid, Cytoxan | II | 3 | NCT03099356 |
| GemcitabineGemcitabin, Gemzar | I–II | 3 | NCT05786924 |
| CetuximabErbitux | I–II | 2 | NCT05786924 |
| CisplatinCis Platinum, Cisplatine | II | 2 | NCT06713057 |
| Defactinib | II | 2 | NCT02465060 |
Sorted by most advanced phase and number of active trials. Showing 15 of 62 drugs.
All 99 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Papillary thyroid cancer 15 drugs
- Ovarian neoplasm 411 drugs
- Colorectal neoplasm 534 drugs
- Non-small-cell lung carcinoma 726 drugs
- Glioma 184 drugs
- Metastasis 493 drugs
- Hematologic neoplasm 216 drugs
- Neoplasm 671 drugs
- Erdheim-Chester disease 6 drugs
- Laryngeal neoplasm 35 drugs
- Multiple myeloma 272 drugs
- Anaplastic thyroid carcinoma 24 drugs
Broader categories
- Endocrine gland neoplasm 3 drugs
- Endocrine system disease 19 drugs
- Thyroid gland disease 14 drugs
- Head and neck neoplasms 184 drugs
- Neoplasm 671 drugs
- Glandular and epithelial neoplasm 12 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D013964 “Thyroid Neoplasms”.